Evoking neuronal activity to improve the lives of Alzheimer’s patients
.webp)
Cognito's headset design concept
We are leading a novel category of disease-modifying therapy in Alzheimer’s disease
Developed with a novel mechanism of action
Research shows that Alzheimer's patients have abnormal neuronal activity in the brain. We're advancing a new way of treating Alzheimer's disease by targeting this abnormal activity.
Promising results from our Phase 2 study
In our Phase 2 OVERTURE trial, significant slowing of disease progression was observed among treated patients through the preservation of cognition, daily function, and whole brain volume. No serious treatment-limiting adverse events were reported.
Designed to fit into patient’s lives
Patients receive this non-invasive treatment from the comfort of their home for one hour each day.
Why do the brain's electrical activities matter?
Neurons communicate through electric signals, creating rhythmic brain activity known as "brain waves." When groups of neurons start firing at the same time, distinct brain waves form at various ranges. One such range is gamma waves, which play an important role in learning and memory. In Alzheimer’s patients, gamma waves are altered, indicating impairment in normal brain function.a
How does our treatment work?
Our novel therapy is designed to evoke gamma wave activity through non-invasive visual and auditory stimulation. In prior clinical studies, it slowed cognitive and functional decline and loss of brain structure among treated Alzheimer's patients.
.webp)

Cognito's headset design concept


Cognito's headset design concept

.webp)


Our treatment received the FDA Breakthrough Device Designation for the treatment of cognitive and functional symptoms associated with Alzheimer’s disease, and we are expanding our approach to many other indications.
Click to enlarge
It all started with a breakthrough from leading MIT neuroscientists
Press, publications & announcements
April 15, 2025
In uncertain times, focus on the mission, Cognito Therapeutics leaders say
April 15, 2025
Harnessing Gamma Frequencies to Modulate Alzheimer Pathology
April 3, 2025
Cognito's device slows Alzheimer's progression, restores brain activity in new OVERTURE readout
April 2, 2025
Cognito Therapeutics data backs Spectris for Alzheimer’s
April 2, 2025
Cognito Therapeutics Announces Spectris™ Data Demonstrating Brain Structural Maintenance and Mechanism of Action in Alzheimer’s Disease at AD/PD™ 2025